Literature DB >> 29133015

Brentuximab vedotin for advanced Hodgkin's lymphoma.

Michelle A Fanale1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29133015     DOI： 10.1016/S1470-2045(17)30845-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin αV β3.

Authors:  André Raposo Moreira Dias; Lizeth Bodero; Ana Martins; Daniela Arosio; Silvia Gazzola; Laura Belvisi; Luca Pignataro; Christian Steinkühler; Alberto Dal Corso; Cesare Gennari; Umberto Piarulli
Journal:  ChemMedChem       Date:  2019-03-22       Impact factor: 3.466

Review 2.  Chemistries and applications of DNA-natural product conjugate.

Authors:  Yuanyuan Chen; Wenting Li; Hang Xing
Journal:  Front Chem       Date:  2022-09-06       Impact factor: 5.545

3.  Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Fontaine Widmayer; Dario Neri
Journal:  J Am Chem Soc       Date:  2018-01-27       Impact factor: 15.419
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.